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Evidence suggests that cystic ﬁbrosis liver disease (CFLD) does not impact on
mortality or morbidity in patients with Cystic Fibrosis (CF). However, the selection
of an appropriate comparison group is central to the interpretation of any differences
in mortality and morbidity in CFLD. The aim of this study was to examine
differences in mortality and morbidity 10 years after the baseline data was collected
on 42 children with CFLD and their 42 age and sex matched controls described
elsewhere [1].
Participants were interviewed at a routine hospital visit or by telephone to determine
hospital admissions, medication use and current well-being. Clinical data was
collected from medical records. No clinical assessment was performed. Medical
records of the deceased (n = 20) were reviewed to determine cause of death. Ethical
approval was obtained, and participants provided informed consent.
Eighty-ﬁve percent (72/84) or the original cohort were available for follow-up;
36 participants with CFLD and 36 CF controls. At follow-up 15/36 (41.7%)
participants with CFLD had died compared to 5/36 (13.9%) CF controls (Relative
Risk = 3.0, 95%CI = 1.2−7.4). Females with CFLD had a 4much higher mortality
risk than males. In a logistic regression model lung function deﬁned as FEV1 <70%
predicted (adjusted odds ratio 4.3 95%CI 1.1–17.3), female gender (adjusted odds
ratio 6.5 95%CI 1.5–27.4) and liver disease (adjusted odds ratio 4.3 (1.1–17.3)
were all independent risk factors for mortality in CF.
Participants with CFLD have a increased mortality risk compared to CF controls
without liver disease, and females with CFLD have a poorer outcome than males
with CFLD.
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Background: Despite >1800 identiﬁed CFTR mutations and increasing availabil-
ity of genetic sequencing, the clinical consequences of most mutations remain
uncertain. Since exocrine pancreatic function is the best phenotypic barometer
of CFTR function, we developed and validated an alternative surrogate marker
of CFTR severity using phenotype data, known as the pancreatic insufﬁciency
prevalence (PIP) score. We evaluated this rating system in 2 cohorts by calculating
the decline in longitudinal serum trypsinogen measurements as a marker of the rate
of pancreatic acinar cell destruction.
Methods: The ﬁrst cohort consisted of Toronto patients who were evaluated
longitudinally since 1980 and the second consisted of newborn screen (NBS)
positive patients with either a conﬁrmed or uncertain diagnosis of CF enrolled from
the Toronto and Verona CF clinics. Patients were excluded if their ﬁrst trypsinogen
measurement was below the lower limit of the reference range or if their ﬁrst and
last measurements were less than one year apart. The rate of decline was calculated
as Dtrypsinogen/Dage. CFTR mutations were classiﬁed by mild (0.25) or severe
(>0.25) PIP scores.
Results: 292 patients were included from the older Toronto cohort and 39 from the
NBS study. In both cohorts those with higher PIP scores (>0.25) had a signiﬁcantly
more rapid decline in their trypsinogen values as compared to the mild group
(P< 0.001).
Conclusion: PIP scores can be used as a tool for predicting the rate of pancreatic
acinar cell destruction and for determining the severity of CFTR mutations.
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Objectives: Several studies have shown that cystic ﬁbrosis related diabetes (CFRD)
is associated with an increase in morbidity and mortality. Improvements in the
quality and implementation of medical care for individuals with cystic ﬁbrosis
(CF) have resulted in a reduction of chronic infections and in an improvement in
survival. The aim of this study was to investigate the incidence of CFRD over the
last 20 years, to identify factors that can predict the development of CFRD and
examine whether CFRD affects lung function and survival rate.
Methods: A retrospective chart review of a birth cohort, including 161 CF patients
born in the period 1975–1994. Patients are followed until 2011. Prospectively
recorded data of BMI, pulmonary function, chronic infection and oral glucose
tolerance test (OGGT) are used. Diabetes is deﬁned as an abnormal OGGT (WHO
criteria’s), consecutive augmented home glucose monitoring and insulin treatment.
Results: In the study period the proportion of children with chronic pulmonary
infection at 10 years declined from 36% to 5% (p = 0.001), whereas the incidence of
CFRD among 11−16 year old patients remained unchanged at 13%. All patients with
CFRD carried CF mutations class I or II. Occurrence of CFRD did not inﬂuence
BMI, pulmonary function nor survival.
Conclusion: Cystic ﬁbrosis related diabetes remained unchanged despite concurrent
decline in proportion of children with chronic pulmonary infection. CFRD was
only related to CF mutations class I or II and did not impair survival in this CF
population.
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Cystic ﬁbrosis-related diabetes (CFRD) is a late manifestation of the disease but
its prevalence is increasing sharply. The oral glucose tolerance test (OGTT), the
standard test for diagnosis of CRFD, is neither sensitive nor speciﬁc.
The aims of this study were to compare different methods of testing for CFRD
diagnosis in children and adolescents with exocrine pancreatic insufﬁciency.
Methods: We prospectively compared for each patient the data from the OGTT,
HOMA-%IR (homeostasis model assessment index of insulin resistance) and
HOMA-%B (homeostasis model assessment index of beta-cell function) with as
the standard the continuous glucose monitoring system (CGMS) data. HOMA-IR =
fasting plasma glucose (FPG) × fasting plasma insulin (FPI)/22.5; HOMA-%B =
(20×FPI)/(FPG− 3.5). Patients were classiﬁed into three groups according to the
2-h glycemia for OGTT and the glycemia over 48h for CGMS: normal glucose
tolerance (NGT), impaired glucose tolerance (IGT) and diabetes mellitus (DM).
Results: 21 patients from 10 to 17 years of age (median: 12.9) were included.
According to the CGMS, 7 had DM, 9 IGT and 5 NGT whereas only 1 patient had
DM and 3 IGT according to the OGTT. All data conﬁrmed that abnormalities of
glucose metabolism were frequent, even in younger children, and associated both
insulin deﬁciency and insulin resistance. The HOMA-%B was the most sensitive
method for screening CFRD (sensitivity 100%, speciﬁcity 50%, negative predictive
value 100%).
Conclusion: CGMS revealed pathological glucose excursions were frequent and
occurred early in life. OGTT should no longer be considered the gold standard for
CFRD diagnosis. HOMA-%B could be used for screening CFRD.
